BackStealth BioTherapeutics Overview

Stealth BioTherapeutics Receivables

Track Stealth BioTherapeutics's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer average / median

Loading

Stealth BioTherapeutics Receivables History

Loading

Stealth BioTherapeutics vs. peers: Receivables Comparison

Loading

Stealth BioTherapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Stealth BioTherapeutics (MITO) FAQ

Stealth BioTherapeutics (MITO) currently reports a receivables of $0 as of March 2022. In the prior-year period, the figure was $0. Use the charts on this page to explore Stealth BioTherapeutics's receivables history and peer comparisons.

Stealth BioTherapeutics's receivables changed from $0 to $0 (period ending March 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Stealth BioTherapeutics reported $0 in receivables as of March 2022. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Stealth BioTherapeutics, and consider following MITO for alerts when major investors trade the stock.

Stealth BioTherapeutics is classified in the Healthcare sector. On receivables, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MITO with unrelated industries.